|
Median age at diagnosis; years (range)
|
50 (18–80)
|
|
Histological type of primary tumour; n (%)
|
|
Ductal
|
228 (88.4)
|
|
Lobular
|
21 (8.1)
|
|
Other subtypes
|
9 (3.5)
|
|
Tumour subgroup; n (%)
|
|
ER-positive
|
184 (71.32)
|
|
PR-positive
|
122 (47.29)
|
|
HR-positive
|
189 (73.3)
|
|
HER2-positive
|
26 (10.2)
|
|
Triple negative
|
58 (22.5)
|
|
ECOG performance status (%)
|
|
0
|
73 (28.3)
|
|
1
|
133 (51.6)
|
|
2
|
46 (17.8)
|
|
3
|
6 (2.3)
|
|
Previous chemotherapy for (neo) adjuvant/advanced disease
|
|
Anthracyclines; n (%)
|
244 (94.6)
|
|
Taxanes; n (%)
|
253 (98.1)
|
|
Capecitabine; n (%)
|
234 (90.7)
|
|
Median prior lines of chemotherapy in the metastatic setting (range)
|
4 (1–9)
|
|
Best response under previous taxane therapy; n (%)
|
|
Complete response
|
20 (7.8)
|
|
Partial response
|
112 (43.8)
|
|
Stable disease
|
78 (30.5)
|
|
Progressive disease
|
33 (12.9)
|
|
Not evaluable
|
13 (5.1)
|
|
Missing
|
2
|
|
Hormonal therapy
|
|
Prior hormonal therapy (HR+ tumours; n [%])
|
184 (97.3)
|
|
Metastatic sites; n (%)
|
|
Visceral metastases
|
223 (86.4)
|
|
Liver
|
174 (67.4)
|
|
Node
|
118 (45.7)
|
|
Lung
|
98 (38.0)
|
|
Brain
|
41 (15.9)
|
|
Serous
|
55 (21.3)
|
|
Skin
|
31 (12.0)
|
|
Bone
|
176 (68.2)
|
|
Other sites
|
26 (10.1)
|
